Peptika.
Cat. 01
Type I · Lyophilised
PK-2026-TB-500
Peptika TB-500 (Thymosin Beta) vial
Lot-tracedEU pharmacyCold-chain 2–8 °C
N° 01 · Healing & Recovery

TB-500 (Thymosin Beta).

Synthetic version of Thymosin β-4 — actin regulation, angiogenesis and cell migration in injured tissue.

Select strengthPer-vial price
Quantity
1
Total
€60.00· 1 vial

Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.

  • ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
  • ✓Patient-named prescription only — dispensed against a valid Rx.
  • ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
  • ✓Cold-chain shipping across EU/EEA — 2–5 working days.
Overview

About TB-500 (Thymosin Beta).

TB-500 is a synthetic version of the active fragment of Thymosin β-4, a 43-amino-acid actin-binding protein abundant in platelets and wound exudate. It plays a central role in actin sequestration and cell migration during tissue repair.

TB-500 is commonly stacked with BPC-157 in clinical practice — the two have complementary mechanisms in the wound-healing cascade.

Mechanism of action

TB-500 binds G-actin, regulating the polymerisation/depolymerisation cycle required for cell migration. It also promotes the differentiation of endothelial cells (driving angiogenesis), suppresses inflammatory cytokine production and inhibits apoptosis of injured cells.

Posology · for information only

Subcutaneous injection, typically 2 mg twice weekly for 4–6 weeks, then a maintenance phase. Doses are adjusted based on injury size and severity.

Your physician sets the prescription. This is descriptive information, not a self-administration guide.

Storage

Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.

Evidence basePreclinical evidence
Indications studied
Tendon & ligament repairMuscle injury recoverySkin healing
Identification & specifications
INN / Name
TB-500 (Thymosin Beta)
Form
Lyophilised vial · subcutaneous injection
Strength
5mg vial
Manufacturing
EU-GMP Annex 1 · Grade A/B
Endotoxins
European Pharmacopoeia 2.6.14 · LAL assay
Identity & purity
HPLC + MS · > 98%
Cold chain
Validated 2–8 °C, monitored end-to-end
Regulatory basis
Directive 2001/83/EC · Article 5(1)
Logistics

2–5 working days

EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.

Legal status

Magistral preparation

Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.

Cross-border

EU prescription recognition

Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.

Same therapeutic axis

Within Healing & Recovery.

All Healing & Recovery preparations
Pre-compounded

Combinations with TB-500 (Thymosin Beta).